NMBOP: 16.19.26 PHARMACIST PRESCRIPTIVE AUTHORITY

Question 1

VACCINE

Q: How must prescriptive authority for vaccines be exercised?

Answer 1

A: Prescriptive authority for vaccines shall be exercised solely in accordance with the written protocol for vaccine prescriptive authority approved by the board. Any pharmacist exercising this authority must maintain a current copy of the approved protocol.

Question 2

VACCINE

Q: What training and education are required for pharmacists exercising prescriptive authority for vaccines?

Answer 2

A:

1. Training Course: The pharmacist must successfully complete a course accredited by the Accreditation Council for Pharmacy Education (ACPE), provided by:
   
   • The Centers for Disease Control and Prevention (CDC); or
   • A similar health authority or professional body approved by the board.
2. Training Content: The training must include:
   
   • Mechanisms of action for vaccines, contraindications, drug interactions, and monitoring after administration;
   • Standards for pediatric, adolescent, and adult immunization practices;
   • Basic immunology and vaccine protection;
   • Vaccine-preventable diseases;
   • Recommended immunization schedules;
   • Vaccine storage management;
   • Biohazard waste disposal and sterile techniques;
   • Informed consent;
   • Physiology and techniques for vaccine administration;
   • Pre and post-vaccine assessment and counseling;
   • Immunization record management;
   • Management of adverse events;
   • Reimbursement procedures and vaccine coverage by federal, state, and local entities.
3. Continuing Education: Pharmacists must complete a minimum of 0.2 CEU of live ACPE-approved vaccine-related continuing education every two years, in addition to other requirements.
4. BLS/CPR Certification: Pharmacists must complete and have current live Basic Life Support/CPR certification.

Question 3

VACCINE

Q: What drugs and vaccines are authorized under prescriptive authority?

Answer 3

A: Prescriptive authority is limited to:
1. Drugs and vaccines delineated in the written protocol approved by the board;
2. Other vaccines as determined by the CDC, Advisory Committee on Immunization Practices (ACIP), or New Mexico Department of Health that may be required to protect public health and safety.

Question 4

VACCINE

Q: What record-keeping requirements are there for vaccines?

Answer 4

A:

1. Prescription Records: The prescribing pharmacist must generate a written or electronic prescription for any dangerous drug authorized.
2. Informed Consent: Informed consent must be documented in accordance with the written protocol and a record of such consent must be maintained in the pharmacy for at least three years.

Question 5

VACCINE

Q: What is the requirement for updating the immunization database?

Answer 5

A: Upon signed consent of the patient or guardian, the pharmacist must update the New Mexico Department of Health Immunization Program’s electronic database (NMSIIS) of any vaccine administered.

Question 6

TC

Q: How must prescriptive authority for tobacco cessation drug therapy be exercised?

Answer 6

A: Prescriptive authority for tobacco cessation drug therapy shall be exercised solely in accordance with the written protocol for tobacco cessation drug therapy approved by the board. Any pharmacist exercising this authority must maintain a current copy of the approved protocol.

Question 7

TC

Q: What training and education are required for pharmacists exercising prescriptive authority for tobacco cessation drug therapy?

Answer 7

A:

1. Training Course: The pharmacist must successfully complete a course accredited by the Accreditation Council for Pharmacy Education (ACPE) in tobacco cessation drug therapy provided by:
   
   • The Department of Health;
   • Health and Human Services; or
   • A similar health authority or professional body approved by the board.
2. Training Content: The training must include:
   
   • Mechanisms of action for contraindications, drug interactions, and monitoring cessation;
   • Current standards for prescribing tobacco cessation drug therapy;
   • Identifying indications for the use of tobacco cessation drug therapy;
   • Interviewing patients to establish the need for tobacco cessation drug therapy;
   • Counseling patients regarding the safety, efficacy, and potential adverse effects of drug products for tobacco cessation;
   • Evaluating the patient’s medical profile for drug interactions;
   • Referring patients for follow-up care with a primary healthcare provider;
   • Informed consent;
   • Record management;
   • Management of adverse events, including identification, appropriate response, documentation, and reporting;
   • Reimbursement procedures and tobacco cessation drug therapy and education coverage by federal, state, and local entities.
3. Continuing Education: Pharmacists must complete a minimum of 0.2 CEU of ACPE-approved tobacco cessation drug therapy-related continuing education every two years, in addition to other requirements.

Question 8

TC

Q: What drugs are authorized for prescriptive authority under tobacco cessation drug therapy?

Answer 8

A: Prescriptive authority is limited to:
1. Tobacco cessation drug therapy, including both prescription and non-prescription therapies.
2. Drugs delineated in the written protocol approved by the board.

Question 9

TC

Q: What are the record-keeping requirements for tobacco cessation drug therapy?

Answer 9

A:

1. Prescription Records: The prescribing pharmacist must generate a written or electronic prescription for any dangerous drug authorized.
2. Informed Consent: Informed consent must be documented in accordance with the approved protocol and a record of such consent maintained in the pharmacy for at least three years.

Question 10

TC

Q: What is required for notification in tobacco cessation drug therapy?

Answer 10

A: Upon signed consent of the patient, the pharmacist shall notify the patient’s designated physician or primary care provider of the tobacco cessation drug therapy prescribed.

Question 11

TB Testing

Q: How must prescriptive authority for Tuberculosis (TB) testing be exercised?

Answer 11

A: Prescriptive authority for TB testing must be exercised solely in accordance with the written protocol for TB testing drug therapy approved by the board. Any pharmacist exercising this authority must maintain a current copy of the approved protocol.

Question 12

TB Testing

Q: What training and education are required for pharmacists exercising prescriptive authority for TB testing?

Answer 12

A:

1. Training Course: The pharmacist must successfully complete training as specified by the New Mexico Department of Health Tuberculosis Department provided by:
   
   • The Department of Health; or
   • A similar health authority or professional body approved by the board.
2. Continuing Education: Pharmacists must complete continuing education as specified by the Centers for Disease Control.

Question 13

TB Testing

Q: What drugs are authorized for use in TB testing?

Answer 13

A:

1. Authorized Drugs: TB skin antigen serum(s).
2. Limitation: Prescriptive authority for TB testing is limited to those drugs delineated in the written protocol approved by the board.

Question 14

TB Testing

Q: What are the record-keeping requirements for TB testing?

Answer 14

A:

1. Prescription Records: The prescribing pharmacist must generate a written or electronic prescription for any TB test administered.
2. Informed Consent: Informed consent must be documented in accordance with the approved protocol for TB testing, and a record of such consent must be maintained in the pharmacy for at least three years.

Question 15

TB Testing

Q: What is required for notification in TB testing?

Answer 15

A: Upon signed consent of the patient, the pharmacist shall notify:
1. The patient’s designated physician or primary care provider.
2. The Department of Health.
This notification is required for any positive TB test.

Question 16

Narcan

Q: How must prescriptive authority for naloxone drug therapy be exercised?

Answer 16

A: Prescriptive authority for naloxone drug therapy must be exercised solely in accordance with the written protocol for naloxone drug therapy approved by the board. Any pharmacist exercising this authority must maintain a current copy of the approved protocol.

Question 17

Narcan

Q: How must prescriptive authority for naloxone drug therapy be exercised?

Answer 17

A: Prescriptive authority for naloxone drug therapy must be exercised solely in accordance with the written protocol for naloxone drug therapy approved by the board. Any pharmacist exercising this authority must maintain a current copy of the approved protocol.

Question 18

Narcan

Q: What are the education and training requirements for pharmacists exercising prescriptive authority for naloxone drug therapy?

Answer 18

A:

1. Training Course: The pharmacist must successfully complete a course accredited by the Accreditation Council for Pharmacy Education (ACPE) in naloxone for opioid overdose drug therapy, provided by:
   
   • The New Mexico Pharmacists Association; or
   • A similar health authority or professional body approved by the board.
2. Content Areas:
   
   • Mechanisms of action.
   • Contraindications.
   • Identifying indications for naloxone use.
   • Patient screening criteria.
   • Counseling and training patients and caregivers on naloxone safety, efficacy, and adverse effects.
   • Evaluating patient’s medical profile for drug interactions.
   • Referring patients for follow-up care.
   • Informed consent.
   • Record management.
   • Management of adverse events.
3. Continuing Education: Pharmacists must complete a minimum of 0.2 CEU of live ACPE approved naloxone drug therapy related continuing education every two years. This is in addition to other requirements in 16.19.4.10 NMAC.

Question 19

Narcan

Q: What drugs are authorized for use in naloxone drug therapy?

Answer 19

A:

1. Authorized Drugs: Prescriptive authority is limited to naloxone and includes any device(s) approved for the administration of naloxone.
2. Limitation: Prescriptive authority is limited to naloxone as delineated in the written protocol approved by the board.

Question 20

Narcan

Q: What are the record-keeping requirements for naloxone dispensing?

Answer 20

A:

1. Prescription Records: The prescribing pharmacist must generate a written or electronic prescription for any naloxone dispensed.
2. Informed Consent: Informed consent must be documented in accordance with the approved protocol for naloxone drug therapy, and a record of such consent must be maintained in the pharmacy for at least three years.

Question 21

Q: What is the notification requirement after dispensing naloxone?

Answer 21

A: Upon signed consent of the patient, the pharmacist must notify the patient’s designated physician or primary care provider within 15 days of naloxone dispensing.

Question 22

Dangerous Drug POC

Q: How must prescriptive authority for dangerous drugs in conjunction with POCT be exercised?

Answer 22

A: Prescriptive authority must be exercised solely in accordance with the written protocol for prescribing dangerous drugs in conjunction with POCT approved by the board. Pharmacists must maintain a current copy of this protocol.

Question 23

Dangerous Drug POC

Q: What are the education and training requirements for pharmacists exercising prescriptive authority for POCT?

Answer 23

A:

1. Training Course: The pharmacist must complete a course accredited by the Accreditation Council for Pharmacy Education (ACPE) for each POCT category for which they exercise prescriptive authority, provided by:
   
   • The New Mexico Pharmacists Association; or
   • A similar health authority or professional body approved by the board.
2. Content Areas:
   
   • Mechanisms of action.
   • Contraindications.
   • Identifying indications for protocol formulary drug therapy.
   • Patient screening, history, and assessment criteria.
   • Counseling and training patients and caregivers on the safety, efficacy, and potential adverse effects of prescribed drugs.
   • Evaluating patient’s medical profile for drug interactions.
   • Patient referrals.
   • Informed consent.
   • Record management.
   • Management of adverse events.
3. Continuing Education: Pharmacists must complete a minimum of 0.2 CEU of live ACPE approved formulary drug therapy related continuing education every two years for each POCT category. This is in addition to other continuing education requirements in 16.19.4.10 NMAC.

Question 24

DAngerous Drug POC

Q: What drugs are authorized for prescribing in conjunction with POCT?

Answer 24

A: Prescriptive authority is limited to those drugs specified in the Board-approved protocol.

Question 25

# Dangerous Drug POC **Q: What are the record-keeping requirements for prescribing dangerous drugs in conjunction with POCT?**

Answer 25

A: 1. **Prescription Records:** The prescribing pharmacist must generate a written or electronic prescription for any medication dispensed under the protocol. 2. **Informed Consent:** Informed consent must be documented according to the approved protocol, and records of such consent must be maintained in the pharmacy for at least three years.

Question 26

# Dangerous Drug POC **Q: What is the notification requirement after dispensing medication in conjunction with POCT?**

Answer 26

A: Upon signed consent of the patient, the pharmacist must notify the patient's designated physician or primary care provider within 15 days of dispensing the medication.